Combining Diabetes and Kidney Disease Treatments: What Patients Should Know

by

Table of Contents

Managing both diabetes and kidney disease simultaneously presents unique challenges that require a comprehensive, coordinated approach to treatment. For the millions of people worldwide living with these interconnected conditions, understanding how therapies work together—and the critical importance of close collaboration with healthcare providers—can make the difference between disease progression and improved long-term outcomes.

Understanding the Diabetes-Kidney Disease Connection

Diabetes is the leading cause of chronic kidney disease (CKD) worldwide, having surpassed primary glomerular disorders in prevalence. The relationship between these two conditions is complex and bidirectional, creating a cycle that can accelerate health complications if not properly managed.

High blood sugar levels characteristic of diabetes damage the delicate blood vessels in the kidneys over time. This vascular damage impairs the kidneys’ ability to filter waste products from the blood effectively. Diabetic kidney disease (DKD) develops in approximately 20-40% of patients with diabetes, with incidence influenced by factors such as diabetes duration, glycemic control, and genetic susceptibility.

Conversely, when kidney function declines, it affects how the body processes and eliminates medications used to manage diabetes. This creates additional complexity in treatment planning, as medication dosages may need adjustment and some drugs may become contraindicated as kidney disease progresses. People with CKD have notably increased risks for premature cardiovascular disease, kidney failure and death, making comprehensive management essential.

The Evolution of Treatment: A Paradigm Shift

For nearly two decades, renin–angiotensin system inhibitors were the only available kidney-protective drugs. However, recent years have witnessed a remarkable transformation in how clinicians approach the combined treatment of diabetes and kidney disease.

Advances have been made in the management of chronic kidney disease with type 2 diabetes, such as with the approved use of renin–angiotensin system inhibitors, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists. This expansion of therapeutic options represents what many experts consider a paradigm shift in diabetes care.

The Rise of Combination Therapy

Combination therapy with evidence-based kidney therapies in diabetic and non-diabetic CKD has emerged as a new standard of care. Rather than relying on a single medication class, healthcare providers now recognize that targeting multiple pathophysiological mechanisms simultaneously offers superior protection for both kidney function and cardiovascular health.

Multiple pathophysiological mechanisms contribute to DKD, and single lifestyle or pharmacological interventions have shown limited efficacy at preserving kidney function. This understanding has driven the shift toward multi-drug approaches that address the complex biology underlying these conditions.

Key Medication Classes for Combined Diabetes and Kidney Disease

Renin-Angiotensin System (RAS) Inhibitors

Blockade of the RAAS remains the foundational therapy for DKD, supported by robust evidence from landmark randomized controlled trials. These medications, which include ACE inhibitors and ARBs (angiotensin receptor blockers), work by reducing pressure within the kidney’s filtering units and decreasing protein leakage into the urine.

Historical trials have demonstrated significant benefits. Captopril reduced the risk of serum creatinine doubling by 48% (P = 0.007), with a more pronounced 76% risk reduction observed in patients with baseline serum creatinine >2.0 mg/dl. In patients with type 2 diabetes, Losartan treatment resulted in a 16% relative reduction in the composite outcome of doubling of serum creatinine, end-stage renal disease (ESRD), or death (P = 0.02).

Both KDIGO and the ADA recommend an ACEi or ARB for treatment of hypertension among people with T1D or T2D who have hypertension and ACR ≥30 mg/g. However, it’s important to note that combination of ACEi and ARBs showed no benefit and more adverse events, particularly hyperkalemia and AKI, and thus avoidance of this combination is recommended.

SGLT2 Inhibitors: A Breakthrough in Kidney Protection

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most significant advances in treating diabetic kidney disease. SGLT2 inhibitors, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, have transformed the management of type 2 diabetes mellitus (T2DM) by providing glucose-lowering efficacy together with cardiovascular and renal protection.

SGLT2 inhibitors reduce kidney tubular glucose reabsorption, weight, systemic blood pressure, intraglomerular pressure, and albuminuria and slow GFR loss through mechanisms that appear independent of glycemia. This means these medications protect the kidneys through multiple pathways beyond simply lowering blood sugar.

Clinical trial evidence has been compelling. Two clinical trials with primary kidney disease outcomes using canagliflozin and dapagliflozin (CREDENCE and DAPA-CKD) demonstrated significant benefit for composite outcomes including end points of substantial eGFR decline, kidney failure, and mortality. SGLT2 inhibitors reduced the risk of worsening of renal function, ESRD or renal death by 45% (HR 0.55, 95% CI 0.48–0.64).

SGLT2 inhibitors appear more effective in mitigating glomerular hyperfiltration and lowering heart failure risk, making them particularly valuable for patients with both diabetes and kidney disease who are also at elevated cardiovascular risk.

GLP-1 Receptor Agonists: Comprehensive Metabolic Benefits

Glucagon-like peptide-1 (GLP-1) receptor agonists have also demonstrated significant kidney-protective effects. GLP-1 RAs have also been shown to improve kidney outcomes, with nonmetabolic mechanisms by which GLP-1 RAs are believed to protect the kidney include anti-inflammatory, antioxidative, and immunomodulatory actions.

GLP-1 receptor agonists are particularly beneficial in reducing albuminuria and atherosclerotic cardiovascular events. In January 2025, the FDA expanded the indication of Ozempic (semaglutide) for adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) to reduce the risk of worsening kidney disease and cardiovascular death, marking an important milestone in recognizing these medications’ kidney-protective properties.

In clinical trials GLP-1 analogs exerted important impact on renal composite outcomes, primarily on macroalbuminuria, possibly through suppression of inflammation-related pathways. The mechanisms extend beyond glucose control to include enhancement of natriuresis and diuresis, contributing to their nephroprotective effects.

Nonsteroidal Mineralocorticoid Receptor Antagonists (MRAs)

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, represents another important addition to the treatment arsenal. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated significant cardiovascular and kidney-protective effects in people with type 2 diabetes mellitus and CKD or HF.

In FIGARO-DKD, the primary composite cardiovascular end point (MACE or hospitalization for HF) was reduced with finerenone compared with placebo. Findings from the FIDELITY individual patient, prespecified combined analysis of both trials (13,191 total participants) demonstrated significant reductions of 18% for the composite cardiovascular outcome; 23% for a composite outcome of doubling of creatinine, kidney failure, or renal death; and 20% for dialysis initiation with a 22% reduction in HF hospitalizations.

One concern with mineralocorticoid receptor antagonists has been the risk of hyperkalemia (elevated potassium levels). However, 2.6% of participants stopped treatment because of hyperkalemia with finerenone compared with 0.9% on placebo, indicating that while monitoring is necessary, the risk is manageable in most patients.

The Power of Combination Therapy: Evidence and Benefits

While individual medication classes offer significant benefits, emerging evidence suggests that combining these therapies may provide even greater protection for patients with diabetes and kidney disease.

Combining SGLT2 Inhibitors with Finerenone

The CONFIDENCE trial provided groundbreaking evidence for combination therapy. At day 180, the reduction in the urinary albumin-to-creatinine ratio with combination therapy was 29% greater than that with finerenone alone (least-squares mean ratio of the difference in the change from baseline, 0.71; 95% confidence interval [CI], 0.61 to 0.82; P<0.001) and 32% greater than that with empagliflozin alone.

Importantly, neither agent, alone or in combination, led to unexpected adverse events. Symptomatic hypotension, acute kidney injury, and hyperkalemia leading to drug discontinuation were uncommon. This safety profile is crucial, as it demonstrates that combination therapy can be implemented without significantly increasing risks to patients.

Besides providing additive protective effects, combination therapy may also help reduce side effects. For instance, using an SGLT2 inhibitor in combination with finerenone helps decrease the risk for high potassium levels.

Multi-Drug Approaches

Along with RAAS inhibitors, these therapies are increasingly regarded as foundational components of DKD management. The concept of “foundational therapy” suggests that rather than using these medications as add-ons or alternatives, they should be considered essential components of treatment for most patients with diabetic kidney disease.

Modeling studies have projected impressive benefits from comprehensive combination therapy. In hypothetical patients aged 50 years, this regimen could extend MACE-free survival by 3.2 years and delay kidney disease progression by 5.5 years. While these are projections rather than direct clinical trial results, they illustrate the potential magnitude of benefit from optimal combination therapy.

Medication Management: Adjustments Based on Kidney Function

One of the most critical aspects of managing diabetes with kidney disease is understanding how declining kidney function affects medication choices and dosing. Both eGFR and albuminuria must be quantified to guide treatment decisions. Quantification of eGFR levels is essential for modifications of medication dosages or restrictions of use.

Metformin Considerations

Metformin, often considered the first-line medication for type 2 diabetes, requires special consideration in patients with kidney disease. SGLT2i treatment without metformin may be reasonable for patients with eGFR too low for safe prescription of metformin, who do not tolerate metformin, or who do not need metformin to achieve glycemic targets.

This represents an important shift in thinking. Historically, declining kidney function meant discontinuing metformin and having fewer medication options. Now, with SGLT2 inhibitors and GLP-1 receptor agonists providing both glucose control and kidney protection, patients have effective alternatives even when metformin becomes contraindicated.

Monitoring Requirements

Regular monitoring is essential for safe and effective medication management. Key parameters include:

  • Estimated glomerular filtration rate (eGFR): Measures how well kidneys are filtering blood
  • Urinary albumin-to-creatinine ratio (UACR): Detects protein leakage into urine, an early sign of kidney damage
  • Serum creatinine: Helps assess kidney function
  • Potassium levels: Particularly important when using RAS inhibitors or mineralocorticoid receptor antagonists
  • Blood pressure: Essential for kidney protection and cardiovascular health
  • Hemoglobin A1c: Measures average blood sugar control over 2-3 months

At any eGFR, the degree of albuminuria is associated with risk of cardiovascular disease (CVD), CKD progression, and mortality, making regular assessment of both parameters crucial for risk stratification and treatment planning.

Diet and Lifestyle: The Foundation of Management

While medications play a crucial role, diet and lifestyle modifications remain fundamental to managing both diabetes and kidney disease effectively. These interventions work synergistically with pharmacological treatments to optimize outcomes.

Dietary Considerations

Managing diet when you have both diabetes and kidney disease requires balancing multiple nutritional goals. A healthcare provider or registered dietitian can help develop a personalized eating plan that addresses both conditions.

Protein intake: While adequate protein is important, excessive protein consumption can burden damaged kidneys. The appropriate amount varies based on the stage of kidney disease and individual factors. Generally, moderate protein restriction may be recommended for advanced kidney disease, but this must be balanced against nutritional needs and diabetes management.

Sodium restriction: Limiting sodium helps control blood pressure and reduce fluid retention, both important for kidney health. Most guidelines recommend limiting sodium to 2,300 mg per day or less, though some patients with advanced kidney disease may need stricter limits.

Carbohydrate management: Controlling carbohydrate intake remains essential for blood sugar management. Working with a dietitian to understand carbohydrate counting and choosing complex carbohydrates over simple sugars can help maintain stable glucose levels.

Potassium and phosphorus: As kidney function declines, the kidneys become less able to regulate potassium and phosphorus levels. Patients with more advanced kidney disease may need to limit foods high in these minerals.

Fluid intake: While adequate hydration is generally beneficial, some patients with advanced kidney disease may need to limit fluid intake to prevent fluid overload.

Physical Activity

Regular physical activity offers multiple benefits for people with diabetes and kidney disease. Exercise helps control blood sugar levels, manage weight, reduce blood pressure, improve cardiovascular health, and enhance overall well-being. Most guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, along with resistance training twice weekly, though individual recommendations should be tailored to each patient’s capabilities and health status.

Weight Management

Maintaining a healthy weight—or losing weight if overweight or obese—can significantly improve both diabetes control and kidney function. Even modest weight loss of 5-10% of body weight can lead to meaningful improvements in blood sugar control, blood pressure, and cardiovascular risk factors.

Smoking Cessation

Smoking accelerates kidney disease progression and increases cardiovascular risk. Quitting smoking is one of the most important steps patients can take to protect their kidneys and overall health. Healthcare providers can offer support through counseling, medications, and referrals to smoking cessation programs.

Blood Pressure Control: A Critical Component

Controlling blood pressure is essential for protecting kidney function and reducing cardiovascular risk in patients with diabetes and kidney disease. High blood pressure damages the blood vessels in the kidneys, accelerating disease progression.

Target blood pressure goals should be individualized based on factors such as age, cardiovascular risk, and kidney disease stage. Generally, guidelines recommend a blood pressure target of less than 130/80 mmHg for most patients with diabetes and kidney disease, though some patients may benefit from more or less stringent targets.

Many of the medications used to treat diabetic kidney disease—including RAS inhibitors, SGLT2 inhibitors, and mineralocorticoid receptor antagonists—also help lower blood pressure, providing dual benefits. However, additional antihypertensive medications may be needed to achieve target blood pressure levels.

Cardiovascular Risk Management

Patients with both diabetes and kidney disease face substantially elevated cardiovascular risk. In fact, cardiovascular disease is the leading cause of death in this population. Comprehensive cardiovascular risk management is therefore essential.

Lipid Management

Controlling cholesterol levels helps reduce cardiovascular risk. Statin therapy is generally recommended for most adults with diabetes and kidney disease, with the intensity of treatment based on individual cardiovascular risk factors. Some patients may also benefit from additional lipid-lowering medications such as ezetimibe or PCSK9 inhibitors.

Antiplatelet Therapy

Low-dose aspirin may be recommended for patients with diabetes and kidney disease who have established cardiovascular disease or are at high cardiovascular risk, though the decision must balance potential benefits against bleeding risks, which may be elevated in patients with kidney disease.

Special Considerations and Emerging Therapies

Dual GLP-1/GIP Receptor Agonists

Newer medications that target multiple pathways are showing promise. The SURMOUNT-2 trial of 938 participants with overweight or obesity with type 2 diabetes showed that tirzepatide reduced albuminuria without adverse changes in eGFR compared with placebo. Early findings with the dual GLP-1/glucose-dependent insulinotropic peptide (GIP) receptor agonist, tirzepatide, suggest benefits on both albuminuria and eGFR decline.

These dual-action medications represent an exciting frontier in diabetes and kidney disease management, potentially offering enhanced benefits through simultaneous activation of multiple beneficial pathways.

Ongoing Research

Additional clinical trials focusing on CKD and cardiovascular outcomes in people with CKD are ongoing and will be reported in the next few years. Ongoing trials are evaluating the optimal sequencing and combination of these agents to further improve outcomes.

Research continues to explore questions such as: What is the optimal sequence for introducing different medication classes? Which combinations provide the greatest benefit for specific patient populations? How can we identify which patients will respond best to particular therapies?

Practical Implementation: Working with Your Healthcare Team

Successfully managing diabetes and kidney disease requires active partnership between patients and their healthcare team, which may include primary care physicians, endocrinologists, nephrologists, dietitians, diabetes educators, pharmacists, and other specialists.

Communication is Key

Open, ongoing communication with healthcare providers is essential. Patients should:

  • Report any new symptoms or side effects promptly
  • Discuss concerns about medications, including cost or difficulty taking them as prescribed
  • Ask questions about treatment goals and how different therapies work
  • Share home blood sugar and blood pressure readings regularly
  • Inform all providers about all medications, supplements, and over-the-counter products being used

Medication Adherence

Taking medications as prescribed is crucial for achieving optimal outcomes. Strategies to improve adherence include:

  • Using pill organizers or medication reminder apps
  • Linking medication-taking to daily routines
  • Understanding the purpose and importance of each medication
  • Discussing cost concerns with healthcare providers, who may be able to suggest lower-cost alternatives or assistance programs
  • Simplifying medication regimens when possible by using combination products or once-daily formulations

Regular Follow-Up

Consistent follow-up appointments allow healthcare providers to:

  • Monitor kidney function and diabetes control through laboratory tests
  • Adjust medications as needed based on kidney function changes
  • Screen for complications
  • Provide ongoing education and support
  • Update treatment plans based on new evidence and guidelines

The frequency of follow-up visits depends on disease severity and stability, but typically ranges from every 3-6 months for stable patients to more frequent visits for those with rapidly changing kidney function or poorly controlled diabetes.

Safety Considerations and Potential Side Effects

While the medications used to treat diabetes and kidney disease are generally safe and well-tolerated, patients should be aware of potential side effects and safety considerations.

SGLT2 Inhibitor Considerations

Despite substantial clinical advantages, therapy requires attention to safety considerations such as volume depletion, genital infections, diabetic ketoacidosis, and potential lower extremity complications.

Genital infections: SGLT2 inhibitors increase glucose in the urine, which can promote yeast infections. These are usually mild and treatable with over-the-counter antifungal medications.

Volume depletion: These medications cause increased urination, which can lead to dehydration, especially in older adults or those taking diuretics. Adequate fluid intake is important.

Diabetic ketoacidosis: Though rare, SGLT2 inhibitors can cause a serious condition called euglycemic diabetic ketoacidosis, where ketones build up even when blood sugar isn’t extremely high. Patients should be educated about symptoms and risk factors.

GLP-1 Receptor Agonist Considerations

Common side effects of GLP-1 receptor agonists include:

  • Gastrointestinal symptoms: Nausea, vomiting, diarrhea, and constipation are common, especially when starting treatment or increasing doses. These symptoms often improve over time.
  • Reduced appetite: While this can be beneficial for weight loss, some patients may experience excessive appetite suppression.
  • Injection site reactions: Since these medications are given by injection, some patients experience mild reactions at injection sites.

Mineralocorticoid Receptor Antagonist Considerations

The primary concern with mineralocorticoid receptor antagonists is hyperkalemia (elevated potassium levels). Regular monitoring of potassium levels is essential, especially when initiating treatment or adjusting doses. Patients should be educated about symptoms of hyperkalemia and the importance of avoiding excessive dietary potassium or potassium supplements without medical supervision.

Understanding Treatment Goals and Expectations

It’s important for patients to understand what treatment can and cannot achieve. While current therapies can significantly slow disease progression and reduce complications, they typically cannot reverse established kidney damage or cure diabetes.

Realistic Goals

Treatment goals should be individualized but generally include:

  • Slowing the progression of kidney disease
  • Maintaining blood sugar levels within target ranges
  • Controlling blood pressure
  • Reducing protein in the urine (albuminuria)
  • Preventing or delaying the need for dialysis or kidney transplantation
  • Reducing cardiovascular risk
  • Maintaining quality of life

Initial Changes in Kidney Function

Patients should be aware that some kidney-protective medications may cause an initial small decrease in kidney function (eGFR). An initial short-term decrease in the eGFR was noted in diabetic patients on SGLT2 inhibitors. However, this decrease was corrected upon long-term administration of the drug, and thereafter, the eGFR remained stable, while it continued to steadily decline in the placebo group.

This initial dip is actually a sign that the medication is working to reduce pressure within the kidneys’ filtering units. Healthcare providers expect this change and will monitor kidney function closely to ensure the decline is within expected ranges.

Financial Considerations and Access to Care

The newer medications for diabetes and kidney disease can be expensive, and cost is a significant barrier for many patients. However, several strategies can help improve access:

  • Insurance coverage: Many insurance plans cover these medications, though prior authorization may be required. Healthcare providers can help with this process.
  • Patient assistance programs: Pharmaceutical manufacturers often offer assistance programs for patients who cannot afford their medications.
  • Generic alternatives: While many of the newest medications don’t yet have generic versions, some older but still effective options do.
  • Discussing cost concerns: Patients should feel comfortable discussing cost concerns with their healthcare providers, who can work to find the most cost-effective treatment approach.

The Future of Diabetes and Kidney Disease Treatment

An important goal for the future pharmacological management of DKD is to individualize treatment with optimal drug combinations based on the underlying pathophysiology and guided by tissue or serum biomarkers. This precision medicine approach would allow healthcare providers to tailor treatments to each patient’s specific disease mechanisms and predict which therapies will be most effective.

Important research gaps remain. These include elucidating underlying mechanisms, identifying reliable predictors of therapeutic response, and defining benefits in populations underrepresented or excluded from clinical trials. Addressing these gaps will facilitate precision medicine by enabling treatment strategies tailored to individual profiles, ultimately improving clinical outcomes.

Emerging areas of research include:

  • Novel therapeutic targets addressing different pathways involved in diabetic kidney disease
  • Biomarkers to predict disease progression and treatment response
  • Artificial intelligence and machine learning to optimize treatment selection
  • Gene therapies and regenerative medicine approaches
  • Improved understanding of the gut-kidney axis and microbiome-based interventions

Key Takeaways for Patients

Managing diabetes and kidney disease together requires a comprehensive, multifaceted approach. Here are the most important points for patients to remember:

  • Multiple medication classes are now available that not only control blood sugar but also protect kidney function and reduce cardiovascular risk. These include SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists, and RAS inhibitors.
  • Combination therapy is increasingly recognized as the standard of care, with evidence showing that using multiple medications targeting different pathways provides superior protection compared to single-drug approaches.
  • Regular monitoring is essential to track kidney function, adjust medications appropriately, and detect complications early. This includes blood tests for kidney function, urine tests for protein, blood sugar monitoring, and blood pressure checks.
  • Lifestyle modifications remain fundamental, including following a kidney-friendly diet, maintaining a healthy weight, exercising regularly, controlling blood pressure, and avoiding smoking.
  • Communication with your healthcare team is crucial. Report symptoms, ask questions, discuss concerns about medications or costs, and work together to develop a treatment plan that fits your individual needs and circumstances.
  • Treatment goals should be individualized based on your specific situation, including disease severity, other health conditions, and personal preferences.
  • Side effects are generally manageable, and the benefits of treatment typically far outweigh the risks. However, being aware of potential side effects and knowing when to contact your healthcare provider is important.
  • The field is rapidly evolving, with new evidence and treatment options emerging regularly. Staying engaged with your healthcare team ensures you can benefit from the latest advances.

Conclusion

The landscape of diabetes and kidney disease management has been transformed in recent years. Driven by the global rise in diabetes, the worldwide burden of CKD has nearly doubled since the 1990s, creating an urgent need for more effective treatments. Fortunately, the emergence of multiple new medication classes with proven kidney-protective and cardiovascular benefits has provided unprecedented opportunities to improve outcomes for patients living with these interconnected conditions.

The integration of these therapies represents a paradigm shift in diabetes care, expanding treatment options for people with diabetes mellitus at risk of kidney failure. Rather than simply managing symptoms, current treatment approaches can meaningfully slow disease progression, reduce complications, and extend both lifespan and quality of life.

However, realizing these benefits requires active engagement from patients, comprehensive care from healthcare providers, and close coordination among the various members of the healthcare team. With building evidence supporting the use of combination therapy, it is crucial to raise awareness of the importance of this treatment approach and develop processes to incorporate new therapies into every day practice to support optimal care and improved outcomes.

For patients navigating the challenges of managing both diabetes and kidney disease, the message is one of hope tempered with realism. While these conditions require ongoing attention and management, the tools available today are more effective than ever before. By working closely with healthcare providers, adhering to treatment plans, making healthy lifestyle choices, and staying informed about new developments, patients can take an active role in protecting their health and optimizing their outcomes.

The journey of managing diabetes and kidney disease is ongoing, but with the right combination of treatments, lifestyle modifications, and healthcare support, patients can look forward to better health and improved quality of life for years to come.

Additional Resources

For more information about managing diabetes and kidney disease, consider exploring these reputable resources:

Remember that while these resources provide valuable information, they should complement—not replace—personalized medical advice from your healthcare providers. Every patient’s situation is unique, and treatment decisions should be made in consultation with qualified healthcare professionals who understand your individual circumstances.